Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 375 results
Flat illustration of a tissue sample and biological chip in a lab setting

Aug 12, 2026

Human Biological Datacenter to Launch to Train World Model of Human Biology

Vivodyne has unveiled an expansive human biological datacenter that aims to revolutionize drug discovery by enabling unprecedented large-scale testing of human tissues.The newly launched facility features 12 robotic HIVE laboratories capable of conducting controlled trials on an estimated 3.1 million large human tissues annually, a capacity that significantly exceeds the total of all U.S. clinical trials combined. Central to this innovation is the Series 2 TissueDisk, a biological chip that can
A glass vial with a drug compound on a lab bench

Aug 12, 2026

Ohio State launches AI-enabled biotech initiative to speed drug discovery

The Ohio State University has unveiled Buckeye BioLaunch, an innovative initiative aimed at accelerating drug discovery through AI technology.This program integrates clinical and genomic data with academic research, leveraging resources from the Ohio State Wexner Medical Center and its Comprehensive Cancer Center, as well as the Colleges of Medicine and Pharmacy. The overarching goal is to establish a robust pipeline for therapeutic development, fostering economic growth and job creation in Cent
Press release cover image

Aug 11, 2026

Bioxytran Reports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID, a Novel Galectin Antagonist Designed with Artificial Intelligence

Once-weekly intravenous treatment was associated with reported improvements in finger function and walking ability, with no adverse events reported during treatment BOSTON, MA, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company pioneering galectin-targeting carbohydrate therapeutics, today announced positive clinical results from the first patient treated with PLICID, an investigational galectin antagonist for Chronic Inflammatory Demyelinat
Press release cover image

Aug 10, 2026

Novo Nordisk and AWS enter strategic partnership to accelerate drug discovery through AI

New AI co-innovation hub in London brings together AWS engineers, AI specialists, and applied scientists alongside Novo Nordisk research and development teams to increase productivity and help reduce the time to market for future medicines.Agreement establishes AWS as Novo Nordisk's preferred cloud provider and strategic AI partner to accelerate drug discovery and modernise its technology infrastructure, preparing for the next generation of medicines. Bagsværd, Denmark, 10 August, 2026 - Novo No
Press release cover image

Aug 10, 2026

Almirall Enters Collaboration With CrystalO for the Discovery and Development of Novel Small Molecules in Medical Dermatology

The collaboration will leverage CrystalO's ion channel small-molecule drug discovery platform and Almirall’s expertise in skin science to jointly advance an innovative small-molecule program in medical dermatology.CrystalO will conduct candidate discovery, optimization, IND-enabling studies and early clinical development to deliver clinical proof of concept (POC), while Almirall will lead subsequent global development, manufacturing and commercialization holding exclusive rights outside mainland
A test tube with green solution in a lab setting

Aug 8, 2026

Build AI Agents for Life Sciences with NVIDIA BioNeMo and Nebius in partnership with J.P.Morgan

NVIDIA, in collaboration with J.P. Morgan and Nebius, is spearheading a workshop aimed at empowering life sciences professionals to harness AI agents for research and drug development.AI agents are revolutionizing the life sciences landscape by enhancing processes such as literature analysis and drug discovery. The upcoming workshop will focus on the BioNeMo Agent Toolkit, which provides developers and life sciences teams with the tools necessary to create AI-driven workflows across various doma
A nanobody protein sample on a lab bench with a research notebook in the background.

Aug 7, 2026

Stanford's AI agents designed a drug Merck later built, too

Stanford University's recent advancements in AI-driven drug development signal a shift from traditional single-agent models to a collaborative network of specialized agents.At the VB Transform 2026 conference, James Zou, a biomedical data science associate professor at Stanford, presented a transformative approach to AI in drug discovery. His team developed a "Virtual Lab" that mimics a physical research environment, utilizing multiple AI agents that specialize in various domains. This innovativ
Press release cover image

Aug 7, 2026

Greenstone Biosciences Receives NIH R61 Grant to Advance Cardiac Fibrosis Therapeutics for Duchenne Muscular Dystrophy

Award supports an iPSC and AI-driven drug discovery program targeting the leading cause of death in DMD patientsPALO ALTO, Calif.--(BUSINESS WIRE)--#BioPharma--Greenstone Biosciences, a biotechnology company advancing New Approach Methodologies (NAMs) for drug discovery, today announced that it has received a Catalyze R61 award from the National Heart, Lung, and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH). The award funds a research program to discover novel d
A minimalist representation of a drug molecule in a dark color scheme.

Aug 6, 2026

Clarivate Scales Agentic AI Across Cortellis to Advance Drug Development

Clarivate has announced the enhancement of its agentic AI capabilities within the Cortellis portfolio, aimed at streamlining drug development processes for life sciences organizations.This expansion allows research and development teams to leverage AI to accelerate discovery, improve safety assessments, and make informed decisions throughout the drug development lifecycle. By integrating AI into existing workflows, researchers can minimize manual tasks and concentrate on strategic scientific dec
Press release cover image

Aug 6, 2026

GenScript and Tamarind Bio Partner to Connect AI Molecular Design with Rapid Lab Validation

Collaboration combines Tamarind Bio's AI-powered molecular design platform with GenScript's wet-lab capabilities to help researchers move from digital concepts to experimental proofPISCATAWAY, N.J. and SAN FRANCISCO, Aug. 5, 2026 /PRNewswire/ -- Artificial intelligence can now generate thousands of potential drug molecules in the time it once took to design one, dramatically expanding what scientists can imagine. Yet deciding which designs merit further investment still depends on experimental p
Press release cover image

Aug 6, 2026

Schrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery

NEW YORK--(BUSINESS WIRE)--#AgenticAI--Schrödinger, Inc. (Nasdaq: SDGR) today announced a strategic agreement with Bristol Myers Squibb (BMS) to deploy Bunsen, Schrödinger's agentic AI co-scientist, within its research organization. Building on a long-standing partnership with BMS where they routinely utilize Schrödinger’s industry-leading computational platform, the new agreement significantly expands the application of Schrödinger’s platform, empowering BMS scientists to explore more scientifi
Press release cover image

Aug 4, 2026

Bioxytran Leverages Artificial Super Intelligence (ASI) to Design Broad-Spectrum Antiviral and Anti-Cancer Metastasis Drugs

Company's ASI-Powered Carbohydrate Design Platform, in Collaboration with University of Minnesota Department of Chemistry, Represents Paradigm Shift in Rational Drug Discovery Boston Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company pioneering innovative therapies for viral diseases and cancer metastasis, today announced the execution of a second Sponsored Research Agreement with the University of Minnesota’s Department of Chemistry